Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-03-17
2010-12-21
Krass, Frederick (Department: 1613)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C514S530000, C514S713000
Reexamination Certificate
active
07855226
ABSTRACT:
Disclosed herein is a method comprising administering a compound to a mammal suffering from an inflammatory bowel disease for the treatment of said disease, said compound having a structure according to Formula Iwherein X, Y, B, R2, R3, R4, R5, R6and n have the meanings found herein.
REFERENCES:
patent: 4117014 (1978-09-01), Pernet et al.
patent: 4994274 (1991-02-01), Chan et al.
patent: 5034413 (1991-07-01), Chan et al.
patent: 5446041 (1995-08-01), Chan et al.
patent: 6437146 (2002-08-01), Hattori et al.
patent: 6531504 (2003-03-01), Burk et al.
patent: 6710072 (2004-03-01), Burk et al.
patent: 1 097 922 (2001-05-01), None
patent: 69101458 (1984-06-01), None
patent: 63002972 (1988-07-01), None
patent: WO2004/071428 (2004-08-01), None
John Wallace, Prostaglandin Biology in Inflammatory Bowel Disease, 30 Gastroenterology Clin. N. Am. 971 (Dec. 2001).
Irwin Singer, et al, Cyclooxegynase 2 is Induced in Colonic Epithelial Cells in Inflammatory Bowel Disease, 115 Gastroenterology 297 (1998).
U.S. Appl. No. 10/365,369, filed Feb. 2003, Donde.
Daniel Podolsky, Inflammatory Bowel Disease, 347 N. Engl. J Med. 417, 421 (Aug. 8, 2002).
Bruce E. Sands, Treatment of Inflammatory Bowel Disease, 118 Gastroenterology S68, S71 (Feb. 2000).
Daniel Podolsky, Inflammatory Bowel Disease, 347 N. Engl. J Med. 417, 417-21 (Aug. 8, 2002).
K. Kabashima, et al.,The prostaglandin receptor EP4 suppresses colitis, mucosal damage and CD4 cell activation in the gut, The Journal of Clinical Investigation, Apr. 2002, vol. 109, No. 7, p. 883-893.
Pernet, Andre G. et al.,Prostaglandin analogs modified at the 10 and 11 positions, Tetrahedron Letters, (41), 1979, pp. 3933-3936.
Plantema, Otto G. et al.,Synthesis of(.+−.)-10.10-dimethylprostaglandin El methyl ester and its 15-epimer, Journal of the Chemical Society, Perkin Transactions 1: Organic and Bio-organic Chemistry (1972-1999), (3), 1978, pp. 304-308.
Plantema, O. G. et al.,Synthesis of 10,10-dimethylprostaglandin E1, Tetrahedron Letters, (51), 1975, 4039.
Hamon, A., et al.,Synthesis of(+−)-and 15-EPI(+−)-10,10-Dimthylprostaglandin E1, Tetrahedron Letters, Elsevier Science Publishers, Amsterdam, NL, No. 3, Jan. 1976, pp. 211-214.
Patent Abstracts of Japan, vol. 0082, No. 18 (C-503), Jun. 10, 1988 & JP 63 002972 A (Nippon Iyakuhin Kogyo KK), Jan. 7, 1988.
Bito, L.Z.,Prostaglandins old concepts and new perspectives, Arch Ophthalmol—vol. 105, Aug. 1987, pp. 1036-10-39.
Bito, L.Z.,Prostaglandins and related compounds as potential ocular therapeutic agents, Chpt. 18, Biological Protection with Prostaglandins, vol. 1, CRC Press, Inc., M.M. Cohen, Editor, 1985.
Bito, L.Z.,Prostaglandins, other eicosanoids, and their derivatives as potential antiglaucoma agents, Chap. 20, pp. 477-505, Glaucoma: Applied pharmacology in medical treatment, Grune & Stratton, Inc., S.Drance, et al., Editors, 1984.
Brooks, D.W., et al.,Asymmetric Microbial Reduction of prochiral 2,2-disubstituted cycloalkanediones, J. Org. Chem. 1987, 52, 3223-3232.
Nilsson, S., et al,PGF2•Increases uveoscleral outflow, Invest Ophthalmol Vis Sci 1987; 28(3 Suppl) :284.
U.S. Appl. No. 07/175,476, filed Dec. 29, 1993, Chan, et al.
Donde Yariv
Donello John E.
Gil Daniel W.
Im Wha-Bin
Kedzie Karen M.
Allergan Inc.
Basquill Sean
Ene Doina G.
Forrestal Kevin J.
Krass Frederick
LandOfFree
Treatment of inflammatory bowel disease does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Treatment of inflammatory bowel disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Treatment of inflammatory bowel disease will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4162744